Cargando…

D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy

Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [(68)Ga]PentixaFor has intrinsic diagnostic value and is used to select patients for personalized CXCR4-targeted radionuclide therapy with its therapeutic radiopharmaceutical companion [(177)Lu]PentixaTher. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luyten, Kaat, Van Loy, Tom, Cawthorne, Christopher, Deroose, Christophe M., Schols, Dominique, Bormans, Guy, Cleeren, Frederik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537445/ https://www.ncbi.nlm.nih.gov/pubmed/34683912 http://dx.doi.org/10.3390/pharmaceutics13101619

Ejemplares similares

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside
por: Ahenkorah, Stephen, et al.
Publicado: (2021)

Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide
por: Tshibangu, Térence, et al.
Publicado: (2020)

3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
por: Ahenkorah, Stephen, et al.
Publicado: (2022)

Signaling properties of the human chemokine receptors CXCR4 and CXCR7 by cellular electric impedance measurements
por: Doijen, Jordi, et al.
Publicado: (2017)

Radiopharmaceuticals for Cancer Imaging and Therapy
por: Bormans, Guy, et al.
Publicado: (2023)

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
por: Cassells, Irwin, et al.
Publicado: (2021)

Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe(3)O(4)@Al(OH)(3) nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution
por: Belderbos, Sarah, et al.
Publicado: (2020)

Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging
por: González-Gómez, Manuel Antonio, et al.
Publicado: (2019)

Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors
por: Van Hout, Anneleen, et al.
Publicado: (2017)

Exploration of Pyrido[3,4-d]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2
por: Van Hoof, Max, et al.
Publicado: (2023)

CXCR7/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells
por: D'huys, Thomas, et al.
Publicado: (2018)

Development of a Novel SPR Assay to Study CXCR4–Ligand Interactions
por: Boonen, Arnaud, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists
por: Shad, Mastaneh Safarnejad, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report
por: Haemels, Maarten, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging
por: Bridoux, Jessica, et al.
Publicado: (2020)

Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
por: Ge, Shushan, et al.
Publicado: (2021)

Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels–Alder reactions. Potential applications for pretargeted in vivo PET imaging
por: Billaud, Emilie M. F., et al.
Publicado: (2017)

Evaluation of [(11)C]NMS-E973 as a PET tracer for in vivo visualisation of HSP90
por: Vermeulen, Koen, et al.
Publicado: (2019)

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets
por: Siemons, Maxime, et al.
Publicado: (2021)

Inhibition of inflammation but not ankylosis by glucocorticoids in mice: further evidence for the entheseal stress hypothesis
por: Braem, Kirsten, et al.
Publicado: (2012)

Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Establishment of a novel CCR5 and CXCR4 expressing CD4(+ )cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists
por: Princen, Katrien, et al.
Publicado: (2004)

Al(18)F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
por: Cleeren, Frederik, et al.
Publicado: (2017)

A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors
por: Santagata, Sara, et al.
Publicado: (2017)

Cellular Electrical Impedance as a Method to Decipher CCR7 Signalling and Biased Agonism
por: Vanalken, Nathan, et al.
Publicado: (2022)

REGA-SIGN: Development of a Novel Set of NanoBRET-Based G Protein Biosensors
por: Boon, Katrijn, et al.
Publicado: (2023)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor
por: Häfliger, Simon, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
por: Cimini, Andrea, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)
por: Spoormans, Kaat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fh13hrv16q0148p45seh9edgkj